X hits on this document

PDF document

Wednesday April 07, 2010 - 10:45 AM EDT - page 2 / 4





2 / 4

  • [P06.162] Characteristics of Switching from Interferon beta to Glatiramer Acetate in Non Respondent Relapsing Remitting Multiple Sclerosis (Poster Session VI: MCelia Oreja-Guevara, Pedro Bermejo-Velasco, Ambrosio Miralles, Exuperio Diez-Tejedor

  • [P06.178] Immunological Response to Glatiramer Acetate in MS Patients after Different Pretreatments The CopImmunoNet Study (Poster Session VI: MNina Kleiner, Tjalf Ziemssen

Azilect® (rasagiline tablets)

  • [PD4.002] The Natural Progression of Clinical Symptoms in Parkinson's Disease May Not Be Faster in the Earlier Stages: Results from the ADAGIO Delayed-Start Study (Poster Discussion Session IV: MApril 14, 2010 at 3:00 PM) Olivier Rascol


  • [PD5.004] Laquinimod Induces Up-Regulation of BDNF in Serum of Patients with Relapsing-Remitting Multiple Sclerosis (Poster Discussion Session V: MJan Thöne, Silvia Seubert, Rebecca Conrad, Giancarlo Comi, Stefan Wiese, Liat Hayardeny, Ralf Gold, Ralf Linker

  • [S41.005] Effect of Laquinimod on Monocyte Subsets (Scientific Sessions: MTal Birnberg, Steffen Jung

  • [P06.208] Axonal Protection Effect of Laquinimod Appears Partially Independent of Its Inhibitory Effect on Inflammation and Demyelination in Experimental Autoimmune Encephalomyelitis (Poster Session VI: MChristiane Wegner, Christine Stadelmann, Emanuel Raymond, Bracha Timan, Liat Hayardeny, Wolfgang Brück


  • [P04.274] Optical Coherence Tomography as Measure of the Effects of Glatiramer Acetate on Axonal Loss in Patients with Acute Optic Neuritis (AON) (Poster Session IV: Neuro-Ophthalmology/Neuro-Otology, April 14, 2010 at 3:00 PM) Mark Kupersmith, Peter Calabresi, Gary Cutter, Robert Sergott, Ron Neumann

Neutralizing Antibody (NAb) Testing

  • [S30.006] The Effect of Neutralizing Antibody Testing on Treatment Patterns Versus Usual Care in Interferon Treated Multiple Sclerosis Patients (Scientific Sessions: MBarbara Green, Edward Fox, Andrew Goodman, Clyde Markowitz, Ronald Murray

About Copaxone®

Copaxone® is indicated for the reduction of the frequency of relapses in RRMS, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. The most common side effects of Copaxone® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain.

Copaxone® (glatiramer acetate injection) is now approved in 51 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries. In North America, Copaxone® is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). In Europe, Copaxone® is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. Copaxone® is a registered trademark of Teva Pharmaceutical Industries Ltd.

See additional important information at http://www.copaxone.com/pdf/PrescribingInformation.pdf or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.


Document info
Document views42
Page views45
Page last viewedWed Jan 18 13:00:03 UTC 2017